Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

d above, offset by the recording of $8.4 million in previously deferred expenses."In 2012, Auxilium accomplished a key goal of achieving full year profitability and we saw good overall commercial growth with both Testim and XIAFLEX, " said Adrian Adams, Chief Executive Officer and President of Auxilium.  "In 2013, we will continue to focus on financial discipline and commercial execution, in addition to preparing for the potential FDA approval and commercial launch of XIAFLEX for the treatment of Peyronie's disease in the fourth quarter, and further developing collagenase for the treatment of multiple potential indications."

Fourth Quarter 2012 and Recent Highlights:

  • In January 2013, the Company issued $350 million aggregate principal amount of 1.50% Convertible Senior Notes Due 2018 in a public offering.  The net proceeds from the offering, including the costs of related note hedge transactions, were approximately $310 million after deducting underwriters' discounts and commissions and estimated offering expenses. 
  • In January 2013, Auxilium expanded its exclusive license for XIAFLEX to include the potential treatment of cellulite as an additional indication for development.  In December 2012, Auxilium announced encouraging top-line 30-day data from the XIAFLEX phase Ib study in cellulite.
  • In December 2012, the U.S. Food and Drug Administration ("FDA") accepted the Company's supplemental Biologics License Application Filing for XIAFLEX for the treatment of Peyronie's Disease ("PD").  Under the Prescription Drug User Fee Act ("PDUFA"), the FDA is expected to take action on the application by September 6, 2013.
  • Fourth Quarter 2012 Financial Details  Total revenues for the three months ended December 31, 2012 were $172.5 compared to $73.3.million recorded in the fourth quarter of 2011.  This increase in net revenues was primarily due to revenue recognition of $93.6 million in deferred up-fr
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Auxilium Announces Appointments to Enhance Leadership Team
    2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
    6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
    7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
    8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management ... over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
    (Date:7/30/2015)... ... July 30, 2015 , ... ... applications and designed for continuous operation up to 1500 bar. The sanitary design ... efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal ...
    (Date:7/29/2015)... 2015: +14% CER / 20% of sales) led the regional performance in the ... as well as solid contributions from Korea, India and ... Middle East / Africa (Q2 2015: +3% ... Turkey and the United Kingdom . ... U.S. HPV sales, on demand across all customer classes. The top seven emerging ...
    (Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
    Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
    ... deCODE genetics,(Nasdaq: DCGN ) today ... laboratory, which processes the company,s deCODEme(TM) personal,genome ... several common,diseases, has been accredited by the ... inspection. The U.S. Centers for Medicare and ...
    ... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
    ... in Groton , Connecticut MORRISVILLE, ... contract manufacturer of APIs, intermediates and Drug Products to the ... pleased to announce the recent award by Pfizer Inc. as ... at Pfizer,s Groton, Connecticut R&D center on May 1, 2009. ...
    Cached Biology Technology:deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2
    (Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
    (Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
    (Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
    Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
    ... of British Columbia and the Child & Family Research Institute ... a type of T cell in type 1 diabetes that ... Also known as juvenile diabetes, type 1 diabetes is an ... with type 1 diabetes, the body attacks itself by destroying ...
    ... to the National Heart, Lung and Blood Institute, the average ... and 30 times a night. This lack of oxygen leads ... disease, an abnormal heart rhythm, or even a fatal cardiac ... exploring the changes in distinct brain regions that contribute to ...
    ... The National Institute of Environmental Health Sciences has ... Shaw for a five-year study of how the ... selection. The project reflects a changing ... advances in molecular toxicology, computational sciences and information ...
    Cached Biology News:Researchers study sleep apnea and lack of oxygen 2Researcher awarded $2.27 million to study environmental effects on gene copy number 2Researcher awarded $2.27 million to study environmental effects on gene copy number 3Researcher awarded $2.27 million to study environmental effects on gene copy number 4
    Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
    ... component of the COP9 signalosome complex (CSN), ... developmental processes. The CSN complex is an ... pathway by mediating the deneddylation of the ... The complex is also involved in phosphorylation ...
    ... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
    Request Info...
    Biology Products: